Using machine learning to unravel long Covid’s mysteries; Pfizer vaccine chief to retire

Researchers are testing machine learning as a way better understand long Covid and its constellation of symptoms. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by   Researchers test the power of machine learning to unravel long Covid's mysteries By Katie Palmer Adobe Researchers are testing machine learning as a way better understand long Covid and its constellation of symptoms. Read More Pfizer vaccine chief Kathrin Jansen, who led Covid effort, to retire By Matthew Herper Dia Dipasupil/Getty Images Kathrin Jansen, the vaccine researcher who led Pfizer's collaboration with BioNTech to develop a Covid-19 vaccine, will retire this year. Read More CDC reports first human H5 bird flu infection in U.S. By Helen Branswell Jamie McDonald/Getty Images The man, described by Colorado health officials as under 40, experienced only fatigue. He is in isolation and is receiving treatment. Read More Sponsor content by Genmab The innovations that may transform cancer treatment How are researchers exploring ways to teach the immune system to take on cancer? Can data sciences improve our understanding of cancer as a disease and help create new medicines? We are unraveling four trends that have the potential to move cancer treatment forward, including approaches from the frontiers of science such as immuno-oncology, translational research and data science, and a different way of working together to nurture innovation. STAT+: Startups are turning to a century-old technology to fuel a resurgence in neuro drug development By Allison DeAngelis Oli Scarff/Getty Images Biotechs are used to turning to genetics as guideposts in developing new medications. Now some are turning to a century-old technology. Read More STAT+: Biogen board slashes CEO's bonus as Aduhelm sales and overall business struggle By Adam Feuerstein and Damian Garde Steven Senn/AP CEO Michael Vounatsos has presided over the volatile development of the Alzheimer's drug Aduhelm and its disastrous commercial rollout. Read More STAT+: Would drugmakers lower their insulin prices if Congress asks nicely? By Rachel Cohrs KEREM YUCEL/AFP via Getty Images Two senators have a new idea to slash insulin costs: dangling incentives to convince drugmakers to lower prices of their own free will. Read More Opinion: HHS needs to step up so CDC's new guidelines won't be 'a bridge to nowhere' for most Americans living with chronic pain By Shravani Durbhakula and Joshua M. Sharfstein Adobe The CDC's pain treatment guidelines will likely recommend comprehensive options that will be available to only a minority of Americans. Read More STAT+: U.S. Trade Rep report sparks concern that a new clash may occur over clinical trial transparency By Ed Silverman Adobe The U.S. Trade Representative claims a European Medicines Agency policy may disclose industry trade secrets contained in clinical study reports. Read More Friday, April 29, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser